{
  "query": "company name aml disputes",
  "timestamp": "2025-09-06 08:05:44",
  "config": {
    "top_k": 5,
    "similarity_threshold": 0.0,
    "reranking_enabled": true,
    "hybrid_search_enabled": true,
    "hybrid_search_weight": 0.7
  },
  "results": [
    {
      "id": 1,
      "text": "ackage or services to a customer which comprises the \nequipment, installation and an agreed number of years of operation and maintenance of the site. The allocation of the price \nto the performance obligations is done based on the standard selling price of each component, driven by budget and taking \ninto accounts some contract negotiation considerations. IBAs contract with the customers typically does not contain \nvariable amounts and the financing component is also considered to be non-significant as milestones payments are spread \nover the project and reflect the progress of IBA in fulfilling its obligations.",
      "similarity_score": 0.057318932813434365,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 726,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 2,
      "text": "2-6 \nActivities, value chain and other business \nrelationships \np7 AR2023 Patient care, what makes our heart beat \np39 AR2023 A committed company / society / supply chain \np47 AR2023 Management report / review of IBA activity sectors \np102 AR2023 Management report / significant acquisitions and divestments in 2023 \np108 AR2023 IFRS consolidated financial \n2-7 \nEmployees \np31 AR2023 A committed company \np66 AR2023 Management report / corporate governance statement / diversity, equity and inclusion policy \np80 AR2023 Management report / corporate governance statement / codes of \nconduct \np191 AR",
      "similarity_score": 0.05425595448216603,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1046,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 3,
      "text": "onformalFLASH6 technology. This builds on \nthe existing relationship between IBA and \nKUMC, who had previously published a joint \nabstract on FLASH technology together during \nthe \nProton \nTherapy \nCo-Operative \nGroup \n(PTCOG) Congress in June 2023. Earlier in \n2023, IBA also announced the first FLASH \nresearch project on a ProteusONE in a clinical \nsetting, with PARTICLE, the proton therapy \ncenter in Leuven, Belgium. IBA also continues to \ndevelop Proton ARC Therapy and completed a \ncomprehensive integration test at the Proton \nTherapy Center of William Beaumont Hospital in \nMichigan, US, at",
      "similarity_score": 0.06485860945809227,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 199,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 4,
      "text": "Onerous contracts for services: The Group recognises a provision of onerous contract when the unavoidable costs of fullfilling the contract exceed the \neconomic benefits expected to be received. This is the case when a service contract is expected to generate negative margin \nin the remaining years. For each contract presenting a risk, the expected margin for the remaining years of the initial term \nis calculated based on the latest available reforecast of the future costs to complete IBAs obligations.",
      "similarity_score": 0.05457730695556957,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 892,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 5,
      "text": "In accordance with the Royal Decree of \nDecember 15, 2015, research costs have been \ncapitalized and amortized over the year since \nJanuary 1, 2016. Development costs in 2023 \nwere, as mentioned before, as from 2023 \nonwards depreciated monthly on a pro rata \ntemporis basis (36 months). For research costs \nall expenditure was depreciated within the year. Investments in tangible assets \nTangible fixed assets represent EUR 29.7 million \nas of December 31, 2023. The increase of EUR \n1.4 million year-on-year is mainly related to \ninvestments for a total amount of EUR 4.3 \nmillion, among \nothers",
      "similarity_score": 0.058122266117787674,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 537,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    }
  ]
}